The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met?
Julie WackerRaphael JoyeLeon GenecandFrederic LadorMaurice BeghettiPublished in: Expert review of clinical pharmacology (2024)
Close collaboration between sponsors, regulators, patients, caregivers, physicians and researchers is necessary to develop efficacious and safe drugs for pediatric pulmonary hypertension. The increasing involvement of patients' and caregivers' participation in the development of clinical trials should help shape future research that is feasible and meaningful to the patients.
Keyphrases
- end stage renal disease
- clinical trial
- pulmonary hypertension
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- primary care
- prognostic factors
- palliative care
- randomized controlled trial
- young adults
- pulmonary artery
- pulmonary arterial hypertension
- open label
- phase ii
- double blind
- phase iii